Legal Intelligencer Quotes Sheller on Risperdal Suit Filings
The Legal Intelligencer 2014-01-15 Individual suit filings related to the antipsychotic drug Risperdal have been increasing in the Philadelphia Court of Common Pleas, First Judicial District leaders say. The uptick has been steady since actions against Johnson & Johnson and its subsidiaries began four years ago, according to the court officials. “We have a group […]
$2.2B Settlement “Leads the Pack”
The $2.2 Billion Settlement with Johnson & Johnson Leads the Pack by Lizzy McLellan, The Legal Intelligencer The Legal Intelligencer reported that the largest verdict and settlement award in Pennsylvania between August 2013 and August 2014 was handled by Sheller, P.C. with a $2.2 billion settlement over healthcare giant Johnson & Johnson and its subsidiary, […]
Sheller Presents on Whistleblower Qui Tam at Bench Bar 2014
2014-09-30 Stephen Sheller presented the feature CLE “American ‘Hustle’: Whistleblowers and Prosecuting False Claims Act Cases” at the Montgomery County Bench Bar conference September 2014. Joined by former Assistant U.S. Attorney Joseph Trautwein, they addressed the complexity of bringing and defending False Claims Act matters by analyzing case developments including their most recent $7.3 million […]
Sheller Quoted in “Dangers of Off-Label Drug Use Kept Secret”
The Toronto Star 2014-06-26 By: David Bruser News Reporter, Jesse McLean Investigative News reporter, Andrew Bailey Data Analyst, Published on Thu Jun 26 2014 A 15-year-old girl who wanted to clear her acne was prescribed the antibiotic minocycline. The teen developed lupus-like symptoms — her immune system attacked her own tissues and organs — and she died. The drug was not approved […]
$7.3M Astellas Pharma Off-Label Marketing and FCA Settlement
Digital Journal 2014-04-16 The whistleblower attorney team of Sheller P.C. announced today that Astellas Pharma U.S., Inc. has agreed to pay $7.3 million to resolve allegations by the Sheller whistleblower client that Astellas violated the False Claims Act by submitting fraudulent claims to government healthcare programs while marketing off-label the antifungal drug Mycamine for use in children. Court […]
Legal Intelligencer Quotes Sheller on Low T Drug Cases
Law.com 2014-03-04 Several products liability attorneys say that the recent appearance of lawsuits nationwide against the manufacturers of testosterone therapy drugs indicates the potential for multidistrict litigation and possibly a new mass tort. Many of the current suits filed in federal courts across the country are against Abbott Laboratories—maker of the topical testosterone therapy drug […]
Sheller Gift Supports Drexel Health Center Expansion and Mission
DrexelNOW 2014-02-21 Drexel University will begin a major expansion of its nurse-managed health center which is nationally recognized as a model of integrated care. With a new gift of $2.5 million from the Sheller Family Foundation, the center at 850 N. 11th Street will break ground for a new wing this spring, with the expanded […]
Sheller Whistleblower Settlement: Florida Pain Practice Pays $750,000
2014-02-25 Sheller, P.C. announced today that Sarasota Pain Associates, P.A. (SPA) and its owner, Dr. Steven Chun, have agreed to pay $750,000 to resolve allegations by the law firm’s whistleblower clients that SPA violated the False Claims Act by submitting false claims to Medicare for procedures and services that he did not perform. During the time […]
Sheller Six Risperdal Settlements, Hundreds More Boys Represented
Sheller in Bloomberg Business on Whistleblowers and J&J $2.2B Settlement
Bloomberg Business Week 2013-12-09 Judy Doetterl was a sales representative for Johnson & Johnson (JNJ) in 2004 when federal agents placed a hidden recording device on her and sent her to tape marketing presentations at a national company sales meeting. U.S. prosecutors wanted to prove claims by Doetterl and others that J&J boosted sales by urging doctors to prescribe […]
